Where Innovations Meets Personalized and Precision Medicine
Subjects = pharmacogenomics
Number of Articles: 3
Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Volume 11, Issue 40, Winter 2026, Pages 16-25

https://doi.org/10.22034/ppmj.2026.2066237.1066

Ramesh Ranjbar, Ramin Shukripour

Abstract Rheumatoid arthritis (RA) is an irreversible systemic autoimmune disorder. The advancement of the illness results in joint deformity and associated functional impairment, which profoundly impacts the standard of life of those affected. This review offers an overview of rheumatoid arthritis (RA), including a broad introduction to the illness, its epidemiology, associated risks, and pathogenesis. It also emphasizes advancements in fundamental research and the many mechanisms of signaling and molecular processes, including genetic variables. Summary of previous studies: In recent decades, researchers have garnered more interest in rheumatoid arthritis. Aberrant signaling pathways in rheumatoid arthritis (RA) constitute a significant area of study for identifying and treating the condition, offering crucial insights for comprehending this complex illness and formulating relevant therapies. The etiology of rheumatoid arthritis is associated with several signaling pathways. Research has repeatedly examined the etiology of rheumatoid arthritis (RA), revealing that both environmental and genetic variables play significant roles in its onset. Additionally, several research indicates that the susceptibility and severity of rheumatoid arthritis (RA) may correlate with the HLA-DRB1 variant, which exhibits the most significant genetic relationship with RA.

Managing Inflammation in Cancer Therapy: Effects of Inflammation Control on Metastasis and Treatment Response

Managing Inflammation in Cancer Therapy: Effects of Inflammation Control on Metastasis and Treatment Response

Volume 10, Issue 39, Autumn 2025, Pages 43-53

https://doi.org/10.22034/ppmj.2025.2066236.1065

Maryam Abbasi Saeidi, Mina i Ekrami Noghab

Abstract Chronic inflammation is a pivotal element in the onset and advancement of cancer. It is crucial in tumor initiation, survival, metastasis, and therapeutic resistance. This study seeks to thoroughly examine the intricate relationship between inflammation and cancer, emphasizing the role of inflammatory processes in tumor formation and their influence on cancer therapy responses. We will investigate the molecular processes behind inflammation-induced cancer progression, analyze how inflammation affects metastasis, and assess its effects on the effectiveness of treatments like chemotherapy, immunotherapy, and targeted therapies. Furthermore, we will investigate prospective therapeutic approaches for addressing inflammation in cancer treatment, emphasizing the necessity for specific modulation to enhance treatment efficacy while mitigating adverse consequences such as immune suppression or heightened infection risk. The report finishes with a discussion on prospective research avenues focused on optimizing inflammation-targeting techniques to augment the efficacy of cancer therapies and better patient outcomes. Ultimately, a deeper understanding of inflammation’s dual role in cancer could pave the way for innovative, more personalized treatment strategies that improve survival and quality of life for patients.

Pharmacogenomics: Unlocking the Future of Personalized Medicine and Precision Drug Development

Pharmacogenomics: Unlocking the Future of Personalized Medicine and Precision Drug Development

Volume 10, Issue 37, Spring 2025, Pages 39-47

https://doi.org/10.22034/pmj.2025.2049550.1050

Sanaz Khosravi Ghareh Cheh

Abstract Pharmacogenomics is a relatively new subject that utilizes genomics and pharmacology to investigate the ways in which genetic variants influence individual responses to treatment with pharmaceuticals. A departure from the conventional "one-size-fits-all" treatment strategy is marked by the advent of pharmacogenomics, which makes it possible to tailor pharmacological regimens to the specific genetic profile of an individual. Significant improvements in pharmacological efficacy, reductions in adverse drug reactions (ADRs), and assistance in the development of drugs that are both safe and effective for a wide range of conditions are all possible outcomes of this domain. The purpose of this study is to investigate the prospective results of pharmacogenomics, with a particular emphasis on the function it plays in the process of drug development and its incorporation into personalized medicine. The purpose of this study is to investigate the genetic characteristics that influence the metabolism, efficacy, and toxicity of drugs, as well as to investigate the regulatory framework that is associated with pharmacogenomics testing. This paper provides a synopsis of the most important genes that are involved in pharmacogenomic responses, as well as a discussion of the potential difficulties that may arise in their practical use and the anticipated breakthroughs in this area of study.